Welcome to Anagrammer Crossword Genius! Keep reading below to see if eporti is an answer to any crossword puzzle or word game (Scrabble, Words With Friends etc). Scroll down to see all the info we have compiled on eporti.
eporti
Searching in Crosswords ...
The answer EPORTI has 0 possible clue(s) in existing crosswords.
Searching in Word Games ...
The word EPORTI is NOT valid in any word game. (Sorry, you cannot play EPORTI in Scrabble, Words With Friends etc)
There are 6 letters in EPORTI ( E1I1O1P3R1T1 )
To search all scrabble anagrams of EPORTI, to go: EPORTI?
Rearrange the letters in EPORTI and see some winning combinations
Scrabble results that can be created with an extra letter added to EPORTI
6 letters out of EPORTI
4 letters out of EPORTI
3 letters out of EPORTI
Searching in Dictionaries ...
Definitions of eporti in various dictionaries:
No definitions found
Word Research / Anagrams and more ...
Keep reading for additional results and analysis below.
Eporti might refer to |
---|
Epoetin alfa (rINN) is a human erythropoietin produced in cell culture using recombinant DNA technology. Authorised by the European Medicines Agency on 28 August 2007, it stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy. * Epoetin is manufactured and marketed by Amgen under the trade name Epogen. Johnson & Johnson subsidiary Janssen Biotech (formerly Ortho Biotech Products, LP), sells the same drug under the name Procrit, pursuant to a product license agreement. The average cost per patient in the U.S. was $8,447 in 2009. Darbepoetin alfa (rINN) is a glycosylation analog of erythropoietin containing two additional N-linked carbohydrate chains, also manufactured and marketed by Amgen, with a trade name of Aranesp. The FDA warnings and safety precautions for Procrit, Epogen and Aranesp are identical. * For several years, epoetin alfa has accounted for the single greatest drug expenditure paid by the U.S. Medicare system; in 2010, the program paid $2 billion for the drug. Raising hemoglobin levels has been found in some studies to be associated with higher risks of thrombotic events, strokes and death. |